Kim Da Woon, Jang Geum Suk, Jung Kyoung Suk, Jung Hyuk Jae, Kim Hyo Jin, Rhee Harin, Seong Eun Young, Song Sang Heon
Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea.
Department of Nursing, Pusan National University Hospital, Busan, Republic of Korea.
Kidney Res Clin Pract. 2022 Nov;41(6):717-729. doi: 10.23876/j.krcp.21.305. Epub 2022 Jul 19.
Whether continuous renal replacement therapy (CRRT) should be applied to critically ill patients with both acute kidney injury (AKI) and cancer remains controversial because of poor expected outcomes. The present study determined prognostic factors for all-cause in-hospital mortality in patients with AKI and cancer undergoing CRRT.
We included 471 patients with AKI and cancer who underwent CRRT at the intensive care unit of a Korean tertiary hospital from 2013 to 2020, and classified them by malignancy type. The primary outcomes were 28-day all-cause mortality rate and prognostic factors for in-hospital mortality. The secondary outcome was renal replacement therapy (RRT) dependency at hospital discharge.
The 28-day mortality rates were 58.8% and 82% in the solid and hematologic malignancy groups, respectively. Body mass index (BMI), presence of oliguria, Sequential Organ Failure Assessment (SOFA) score, and albumin level were common predictors of 28-day mortality in the solid and hematologic malignancy groups. A high heart rate and the presence of severe acidosis were prognostic factors only in the solid malignancy group. Among the survivors, the proportion with RRT dependency was 25.0% and 33.3% in the solid and hematologic malignancy groups, respectively.
The 28-day mortality rate of cancer patients with AKI undergoing CRRT was high in both the solid and hematologic malignancy groups. BMI, presence of oliguria, SOFA score, and albumin level were common predictors of 28-day mortality in the solid and hematologic malignancy groups, but a high heart rate and severe acidosis were prognostic factors only in the solid malignancy group.
对于合并急性肾损伤(AKI)和癌症的危重症患者是否应采用持续肾脏替代治疗(CRRT),由于预期预后不佳,仍存在争议。本研究确定了接受CRRT的AKI合并癌症患者全因院内死亡率的预后因素。
我们纳入了2013年至2020年在韩国一家三级医院重症监护病房接受CRRT的471例AKI合并癌症患者,并根据恶性肿瘤类型对他们进行分类。主要结局为28天全因死亡率和院内死亡的预后因素。次要结局为出院时对肾脏替代治疗(RRT)的依赖情况。
实体恶性肿瘤组和血液系统恶性肿瘤组的28天死亡率分别为58.8%和82%。体重指数(BMI)、少尿的存在、序贯器官衰竭评估(SOFA)评分和白蛋白水平是实体恶性肿瘤组和血液系统恶性肿瘤组28天死亡率的常见预测因素。高心率和严重酸中毒仅是实体恶性肿瘤组的预后因素。在幸存者中,实体恶性肿瘤组和血液系统恶性肿瘤组对RRT依赖的比例分别为25.0%和33.3%。
接受CRRT的AKI合并癌症患者,实体恶性肿瘤组和血液系统恶性肿瘤组的28天死亡率均较高。BMI、少尿的存在、SOFA评分和白蛋白水平是实体恶性肿瘤组和血液系统恶性肿瘤组28天死亡率的常见预测因素,但高心率和严重酸中毒仅是实体恶性肿瘤组的预后因素。